• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

拉丁美洲的替代人乳头瘤病毒疫苗接种方案。

Alternative HPV vaccination schedules in Latin America.

作者信息

Robles Claudia, Hernández María de la Luz, Almonte Maribel

机构信息

Prevention and Implementation Group, International Agency for Research on Cancer (IARC/WHO). Lyon, France.

Cancer Epidemiology Research Program, Catalan Institute of Oncology, L'Hospitalet. Barcelona, Spain.

出版信息

Salud Publica Mex. 2018 Nov-Dic;60(6):693-702. doi: 10.21149/9810.

DOI:10.21149/9810
PMID:30699274
Abstract

In 2008, the first HPV vaccination program in Latin America started in Panama, targeting girls aged 10-11 years with a 3-dose vaccine schedule, an initiative that was to be followed by other Latin American countries after local feasibility and population acceptability evaluations were completed. A 3-dose vaccine regimen over six months was originally chosen for HPV vaccines, copying the Hepatitis B vaccine schedule (0, 1-2, 6 months). Alternative vaccine schedules have been proposed afterwards based on: i) noninferior immunogenicity or immune response levels compared to those at which clinical efficacy has been proven (i.e., those observed in a 3-dose HPV vaccine schedule in women aged 15-26), and, ii) proven efficacy in clinical trials and/or effectiveness among women who were provided less than three doses due to a lack of adherence to a 3-dose vaccine schedule. In 2014, based on the available evidence and the potential increase in coverage by expansion of vaccination target groups, particularly in low and middle income countries (LMIC), the World Health Organization recommended a 2-dose schedule with at least a 6-month interval between doses for females up to 15 years of age and a 3-dose schedule for older women. More recently, it has been suggested that 1-dose HPV vaccination schemes may provide enough protection against HPV infection and may speed up the introduction of HPV vaccination in LMIC, where most needed.

摘要

2008年,拉丁美洲首个HPV疫苗接种计划在巴拿马启动,目标人群为10至11岁的女孩,采用三剂疫苗接种方案。在当地完成可行性和人群可接受性评估后,其他拉丁美洲国家也将效仿这一举措。HPV疫苗最初选择在六个月内接种三剂,效仿乙肝疫苗接种方案(0、1-2、6个月)。此后,基于以下因素提出了替代疫苗接种方案:i)与已证明临床疗效的免疫原性或免疫反应水平相比不劣(即15至26岁女性三剂HPV疫苗接种方案中观察到的水平);ii)在临床试验中已证明的疗效和/或在因未坚持三剂疫苗接种方案而接种少于三剂的女性中的有效性。2014年,基于现有证据以及通过扩大疫苗接种目标群体(特别是在低收入和中等收入国家)可能提高的覆盖率,世界卫生组织建议15岁及以下女性采用两剂接种方案,剂次间隔至少6个月,年龄较大的女性采用三剂接种方案。最近,有人提出单剂HPV疫苗接种方案可能提供足够的保护以预防HPV感染,并且可能加快在最需要的低收入和中等收入国家引入HPV疫苗接种。

相似文献

1
Alternative HPV vaccination schedules in Latin America.拉丁美洲的替代人乳头瘤病毒疫苗接种方案。
Salud Publica Mex. 2018 Nov-Dic;60(6):693-702. doi: 10.21149/9810.
2
Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.不同人乳头瘤病毒(HPV)疫苗类型及接种程序对预防女性和男性HPV相关疾病的比较。
Cochrane Database Syst Rev. 2019 Nov 22;2019(11):CD013479. doi: 10.1002/14651858.CD013479.
3
Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.关于在青春期前女孩中,两剂与三剂 HPV 免疫接种方案相比免疫原性非劣效性的不确定证据:系统评价和荟萃分析。
J Infect. 2015 Jul;71(1):61-73. doi: 10.1016/j.jinf.2015.02.005. Epub 2015 Feb 21.
4
Two-dose schedules for human papillomavirus vaccine: Systematic review and meta-analysis.人乳头瘤病毒疫苗的两剂接种方案:系统评价与荟萃分析
Vaccine. 2017 May 19;35(22):2892-2901. doi: 10.1016/j.vaccine.2017.03.096. Epub 2017 Apr 25.
5
Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials.单剂人乳头瘤病毒疫苗与不接种疫苗或标准三剂和两剂疫苗接种方案的疗效和免疫原性:来自临床试验的证据的系统评价。
Vaccine. 2020 Feb 5;38(6):1302-1314. doi: 10.1016/j.vaccine.2019.12.017. Epub 2019 Dec 20.
6
Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial.越南 HPV 疫苗替代接种程序的免疫原性和反应原性:一项集群随机非劣效试验。
JAMA. 2011 Apr 13;305(14):1424-31. doi: 10.1001/jama.2011.407.
7
Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose.11 至 13 岁女孩采用不同免疫程序接种四价 HPV 疫苗后的免疫原性:第 3 剂后 29 至 32 个月的结果。
J Infect Dis. 2013 Oct 15;208(8):1325-34. doi: 10.1093/infdis/jit363. Epub 2013 Jul 30.
8
Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women.二剂程序在女童和男童中与三剂程序在女性中比较的 9 价 HPV 疫苗免疫原性。
JAMA. 2016 Dec 13;316(22):2411-2421. doi: 10.1001/jama.2016.17615.
9
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.两剂 HPV 疫苗在青少年中的免疫原性与三剂 HPV 疫苗在年轻女性中的免疫原性比较:一项随机临床试验。
JAMA. 2013 May 1;309(17):1793-802. doi: 10.1001/jama.2013.1625.
10
Realities of alternative HPV vaccination schedules.替代HPV疫苗接种程序的实际情况。
Salud Publica Mex. 2018 Nov-Dic;60(6):617-620. doi: 10.21149/10190.

引用本文的文献

1
Vaccine Confidence During Public Health Challenges and Prior to HPV Vaccine Introduction in Mali.马里公共卫生挑战期间及人乳头瘤病毒疫苗引入之前的疫苗信心
Vaccines (Basel). 2025 May 17;13(5):535. doi: 10.3390/vaccines13050535.
2
Human Papilloma Virus Vaccination as a Strategy to Eliminate Cervical Cancer: Challenges and Opportunities.人乳头瘤病毒疫苗接种作为消除宫颈癌的策略:挑战与机遇
Vaccines (Basel). 2025 Mar 11;13(3):297. doi: 10.3390/vaccines13030297.
3
Multiple HPV Infections and Viral Load Association in Persistent Cervical Lesions in Mexican Women.
墨西哥女性持续性宫颈病变中 HPV 多重感染及其病毒载量的相关性研究
Viruses. 2020 Mar 31;12(4):380. doi: 10.3390/v12040380.